Labeling stem cells in vitro for identification of their differentiated phenotypes after grafting into the CNS.
Labeling stem cells for CNS grafting is an empirical process. Specific protocols cannot be given that will work for all cell types and all applications. We have provided the range of conditions under which various labels have been successfully used in CNS grafting studies, and delineated the parameters that have to be empirically established. Given a clear understanding of the limitations of the respective labels, and the expected outcome of the grafting experiment, these labeling guidelines should enable any investigator to develop a successful labeling approach. Our own personal bias is to use labels that cannot be transferred to host cells. We prefer BrdU, or more often, retrovirally delivered EGFP or lacZ. However, each investigator will have to decide what is optimal for their own cell population and experimental design.
Cao
Qi-lin
QL
Kentucky Spinal Cord Injury Research Center, Department of Neurological Surgery, University of Louisville, School of Medicine, Louisville, KY, USA.
Onifer
Stephen M
SM
Whittemore
Scott R
SR
D000818:Animals; D000906:Antibodies / Q000276:immunology; D000941:Antigens / Q000276:immunology; D015415:Biomarkers / Q000032:analysis*; D016380:Brain Tissue Transplantation / Q000295:instrumentation / Q000379:methods*; D001973:Bromodeoxyuridine; D002454:Cell Differentiation / Q000235:genetics*; D017930:Genes, Reporter / Q000235:genetics*; D005822:Genetic Vectors; D006085:Graft Survival / Q000235:genetics; D007150:Immunohistochemistry / Q000379:methods; D051379:Mice; D009419:Nerve Tissue Proteins / Q000276:immunology; D009457:Neuroglia / Q000166:cytology* / Q000378:metabolism; D009474:Neurons / Q000166:cytology* / Q000378:metabolism; D010641:Phenotype; D051381:Rats; D033581:Stem Cell Transplantation; D013234:Stem Cells / Q000166:cytology* / Q000378:metabolism
D000906:Antibodies; D000941:Antigens; D015415:Biomarkers; D009419:Nerve Tissue Proteins; D001973:Bromodeoxyuridine